ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ono Pharmaceutical Co. Ltd is currently conducting a Phase 2 clinical study titled ‘A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures.’ The study aims to assess the long-term safety and tolerability of cenobamate, a drug intended for Japanese patients with partial onset seizures, which is a significant concern in epilepsy management.
The intervention being tested is cenobamate, an experimental drug administered orally once daily. Its purpose is to provide treatment for partial onset seizures, potentially offering a new therapeutic option for patients.
This interventional study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. The open-label design allows all participants and researchers to know the treatment being administered, which is crucial for long-term safety evaluation.
The study began on August 8, 2024, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on June 1, 2025, indicating ongoing recruitment and progress in the study.
The successful development of cenobamate could positively impact Ono Pharmaceutical’s stock performance by strengthening its portfolio in the epilepsy treatment market. This update may also influence investor sentiment, especially as the company competes with other pharmaceutical firms in the neurological disorder space.
The study is ongoing, and further details are available on the ClinicalTrials portal.